Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for iBio, Inc. (IBIO : AMEX)

• Company Description    Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware. Number of Employees: 75

• Price / Volume Information    Yesterday's Closing Price: $0.28 Daily Weekly Monthly 20 Day Moving Average: 2,050,591 shares Shares Outstanding: 218.17 (millions) Market Capitalization: $61.09 (millions) Beta: -4.65 52 Week High: $1.76 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.11% 0.11% 12 Week -14.45% -5.96% Year To Date -49.00% -48.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8800 HSC Parkway - Bryan,TX 77807 USA ph: 979-446-0027 fax: 302-356-1173 ir@ibioinc.com http://www.ibioinc.com

• General Corporate Information    Officers Thomas F. Isett - Chairman and Chief Executive Officer Robert Lutz - Chief Financial Officer Linda Armstrong - Director Alexandra Kropotova - Director William Clark - Director Peer Information iBio, Inc. (CORR.) iBio, Inc. (RSPI) iBio, Inc. (CGXP) iBio, Inc. (BGEN) iBio, Inc. (GTBP) iBio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 451033203 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/26/22 Share - Related Items Shares Outstanding: 218.17 Most Recent Split Date: 6.00 (0.10:1) Beta: -4.65 Market Capitalization: $61.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/26/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.77 Price/Cash Flow: - Price / Sales: 21.72 EPS Growth vs. Year Ago Period: -50.00% vs. Previous Quarter: -20.00% Sales Growth vs. Year Ago Period: 153.99% vs. Previous Quarter: 1,056.55% ROE 03/31/22 - -45.72 12/31/21 - -38.17 09/30/21 - -33.06 ROA 03/31/22 - -32.55 12/31/21 - -27.58 09/30/21 - -24.06 Current Ratio 03/31/22 - 7.28 12/31/21 - 8.09 09/30/21 - 11.09 Quick Ratio 03/31/22 - - 12/31/21 - 7.85 09/30/21 - 11.02 Operating Margin 03/31/22 - -1,540.45 12/31/21 - -2,361.10 09/30/21 - -1,602.81 Net Margin 03/31/22 - -1,177.85 12/31/21 - -1,737.25 09/30/21 - -1,133.19 Pre-Tax Margin 03/31/22 - -1,177.96 12/31/21 - -1,737.49 09/30/21 - -1,133.47 Book Value 03/31/22 - 0.36 12/31/21 - 0.42 09/30/21 - 0.46 Inventory Turnover 03/31/22 - 0.58 12/31/21 - 1.71 09/30/21 - 2.64 Debt-to-Equity 03/31/22 - 0.28 12/31/21 - 0.24 09/30/21 - 0.31 Debt-to-Capital 03/31/22 - 21.83 12/31/21 - 19.61 09/30/21 - 23.95

Powered by Zacks Investment Research ©